ProCE Banner Activity

EXTEND Open-Label Extension: Withdrawal of csDMARDs in Patients With Rheumatoid Arthritis Receiving Sarilumab

Slideset Download
Conference Coverage
Withdrawal of csDMARDs had no significant effect on ongoing clinical response compared with continuation of csDMARDs or use of sarilumab monotherapy.

Released: June 27, 2019

Expiration: June 25, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Lilly

Sanofi Genzyme and Regeneron Pharmaceuticals